FDA Approves Pediatric Risankizumab - Top-Institutions - MDSpire

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Northwestern University Feinberg School of Medicine
    Northwestern University Feinberg School of Medicine

    Chicago, Illinois

    Key Differentiators

    • Pediatrics

Original Source(s)

FDA Approves Pediatric Risankizumab

  • by Kathryn Wighton

  • June 29, 2026

Related Content

Efficacy and anthropometric predictors of negative-pressure therapy for recurrent concealed penis in pediatric patients

Nonlinear Association of Serum Sodium with Urine Output in Postoperative Pediatric Cardiac Patients Receiving Furosemide: A Retrospective Study

Case report: Pediatric vascular Behçet’s disease with prominent arterial involvement: a case series of five patients